Literature DB >> 2471026

Clinical evaluation of treatment with interferon.

H Strander1.   

Abstract

Interferons (IFNs) are biological response modifiers with antiviral and antitumoral efficacy. They are produced by almost all cells and the IFN system as a whole is an integrated part of body regulation and defence. Exogenous IFN therapy has been used since 1970 and some viral and tumor diseases respond to such therapy. Doses and schedules giving optimal effects are being worked out. IFNs are probably most valuable for the treatment of some chronic viral diseases and their effects on some benign and malignant tumors hold considerable promise for future improved applications.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471026     DOI: 10.1007/bf02985228

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  15 in total

Review 1.  How does interferon inhibit tumor growth?

Authors:  I Gresser
Journal:  Interferon       Date:  1985

Review 2.  Interferon treatment of human neoplasia.

Authors:  H Strander
Journal:  Adv Cancer Res       Date:  1986       Impact factor: 6.242

Review 3.  Interferon treatment of renal cell carcinoma. Current status and future prospects.

Authors:  S E Krown
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

Review 4.  Human interferons: structure and function.

Authors:  K C Zoon
Journal:  Interferon       Date:  1987

Review 5.  Therapy of chronic myelogenous leukemia: chemotherapy and interferons.

Authors:  M Talpaz; H M Kantarjian; R Kurzrock; J Gutterman
Journal:  Semin Hematol       Date:  1988-01       Impact factor: 3.851

6.  Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors.

Authors:  S E Krown; F X Real; S Vadhan-Raj; S Cunningham-Rundles; M Krim; G Wong; H F Oettgen
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

7.  Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas.

Authors:  P A Bunn; D C Ihde; K A Foon
Journal:  Int J Cancer Suppl       Date:  1987

8.  Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs.

Authors:  C E Welander
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

9.  Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome.

Authors:  K Oberg; K Funa; G Alm
Journal:  N Engl J Med       Date:  1983-07-21       Impact factor: 91.245

10.  Interferon therapy of non-Hodgkin's lymphoma.

Authors:  K A Foon; M S Roth; P A Bunn
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.